Market Cap 24.60M
Revenue (ttm) 0.00
Net Income (ttm) -55.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 85,300
Avg Vol 197,968
Day's Range N/A - N/A
Shares Out 35.14M
Stochastic %K 10%
Beta 2.95
Analysts Strong Sell
Price Target $7.71

Company Profile

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 410 0266
Address:
11250 El Camino Real, Suite 100, San Diego, United States
Fellforit
Fellforit Jun. 24 at 9:13 PM
$SKYE hey mission trader--while you're swinging for the fences "hoping" for a foul tip, ive been hitting home runs!!! Has your man Dhillion given you a participation trophy yet??
0 · Reply
MissionaryTrader
MissionaryTrader Jun. 24 at 5:03 PM
$SKYE added again
1 · Reply
MissionaryTrader
MissionaryTrader Jun. 23 at 4:16 PM
$SKYE added
1 · Reply
YazzJr
YazzJr Jun. 23 at 12:55 PM
$SKYE Interesting video. Muscle loss is a real issue when taking a GLP-1's. There are things people can do to counter-act that like working out and eating a lot of protein but, let's face it, the people who need the GLP-1's are people who never worked out or minded their protein intake so changing that lifestyle will be hard. This is why Nimicimab is so important. It works for losing the fat but, it doesn't effect muscle tissue at all. Anyway, interesting video for those who care to watch. https://www.youtube.com/watch?v=Zit5we5Ss18
0 · Reply
Lucoz12
Lucoz12 Jun. 23 at 12:16 PM
$SKYE new 8-K out today, worth reading carefully because it's not the PIPE everyone was waiting for and it's not a delisting either. Nasdaq approved SKYE's transfer from the Nasdaq Global Market to the Nasdaq Capital Market effective June 23. The Capital Market only requires $3M stockholders' equity instead of the $10M that triggered the deficiency, and with equity around $9M they're now comfortably compliant. Same ticker, same exchange, no forced ETF selling. Basically they solved the equity problem without diluting, they lowered the bar instead of issuing emergency shares at a low price. Two things still open, the sub-$1 bid price with the September deadline so a reverse split is still possible, and the cash side. But the June 29 pressure is off the table now, they bought themselves time to raise capital from a less desperate position or to close a deal without having to dilute first 🤞🏻
1 · Reply
Blinddartthrowerl
Blinddartthrowerl Jun. 18 at 4:00 AM
$SKYE The RS will probably be 1:25 this time - thats a lot better than the last one 1:250!!! I’m a triathelete too!!!!
0 · Reply
Blinddartthrowerl
Blinddartthrowerl Jun. 18 at 3:56 AM
$SKYE Did these guys cure Glaucoma yet?
0 · Reply
Blinddartthrowerl
Blinddartthrowerl Jun. 18 at 3:55 AM
$SKYE Did these guys cure Glaucoma yet?
0 · Reply
TheMoneyDude777
TheMoneyDude777 Jun. 16 at 9:07 PM
$SKYE thank you awesome job! now though bad management lets get this to .5 To the floor!!!
1 · Reply
TheMoneyDude777
TheMoneyDude777 Jun. 16 at 1:47 PM
$SKYE close today under .68! yes summer dilution!
0 · Reply
Latest News on SKYE
Skye Bioscience Transcript: AGM 2026

May 26, 2026, 1:00 PM EDT - 4 weeks ago

Skye Bioscience Transcript: AGM 2026


Skye Bioscience reports Q1 EPS (32c), consensus (32c)

2026-05-11T21:09:20.000Z - 6 weeks ago

Skye Bioscience reports Q1 EPS (32c), consensus (32c)


Skye Bioscience Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 6 weeks ago

Skye Bioscience Quarterly report: Q1 2026


Skye Bioscience Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 6 weeks ago

Skye Bioscience Earnings release: Q1 2026


Skye Bioscience Slides: Corporate presentation

May 11, 2026, 7:00 AM EDT - 6 weeks ago

Skye Bioscience Slides: Corporate presentation


Skye Bioscience Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 2 months ago

Skye Bioscience Proxy statement: Proxy filing


Skye Bioscience Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 2 months ago

Skye Bioscience Proxy statement: Proxy filing


Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Apr 7, 2026, 7:00 AM EDT - 2 months ago

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit


Skye Bioscience Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 2 months ago

Skye Bioscience Proxy statement: Proxy filing


Skye Bioscience Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 2 months ago

Skye Bioscience Proxy statement: Proxy filing


Skye Bioscience Slides: Corporate presentation

Apr 3, 2026, 7:00 AM EDT - 2 months ago

Skye Bioscience Slides: Corporate presentation


Skye Bioscience Earnings Call Transcript: Q4 2025

Mar 10, 2026, 4:30 PM EDT - 3 months ago

Skye Bioscience Earnings Call Transcript: Q4 2025


Skye Bioscience Earnings release: Q4 2025

Mar 10, 2026, 4:30 PM EDT - 3 months ago

Skye Bioscience Earnings release: Q4 2025


Skye Bioscience Annual report: Q4 2025

Mar 10, 2026, 4:30 PM EDT - 3 months ago

Skye Bioscience Annual report: Q4 2025


Skye Bioscience Slides: Q4 2025

Mar 10, 2026, 4:30 PM EDT - 3 months ago

Skye Bioscience Slides: Q4 2025


Skye Bioscience reports Q4 EPS (36c), consensus (31c)

2026-03-10T20:12:08.000Z - 3 months ago

Skye Bioscience reports Q4 EPS (36c), consensus (31c)


Skye Bioscience Slides: Corporate presentation

Feb 21, 2026, 6:00 AM EST - 4 months ago

Skye Bioscience Slides: Corporate presentation


Skye Bioscience presents poster on efficacy of Nimacimab

2026-01-29T12:20:16.000Z - 5 months ago

Skye Bioscience presents poster on efficacy of Nimacimab


Skye Bioscience to Present Poster at Keystone Obesity Conference

Jan 21, 2026, 7:00 AM EST - 5 months ago

Skye Bioscience to Present Poster at Keystone Obesity Conference


Skye Bioscience provides 2026 corporate outlook

2026-01-12T12:12:34.000Z - 5 months ago

Skye Bioscience provides 2026 corporate outlook


Skye Provides 2026 Corporate Outlook

Jan 12, 2026, 7:00 AM EST - 5 months ago

Skye Provides 2026 Corporate Outlook


Skye Bioscience Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 8 months ago

Skye Bioscience Earnings Call Transcript: Q3 2025


Skye Bioscience Earnings release: Q3 2025

Nov 10, 2025, 4:30 PM EST - 8 months ago

Skye Bioscience Earnings release: Q3 2025


Skye Bioscience Quarterly report: Q3 2025

Nov 10, 2025, 4:30 PM EST - 8 months ago

Skye Bioscience Quarterly report: Q3 2025


Skye Bioscience reports Q3 EPS (32c), consensus (32c)

2025-11-10T21:16:34.000Z - 8 months ago

Skye Bioscience reports Q3 EPS (32c), consensus (32c)


Skye Bioscience downgraded to Hold from Buy at Craig-Hallum

2025-10-06T16:15:27.000Z - 9 months ago

Skye Bioscience downgraded to Hold from Buy at Craig-Hallum


Why Is Skye Bioscience Stock Down 60% Today?

2025-10-06T12:19:20.000Z - 9 months ago

Why Is Skye Bioscience Stock Down 60% Today?


Skye Bioscience Transcript: Study Update

Oct 6, 2025, 8:00 AM EDT - 9 months ago

Skye Bioscience Transcript: Study Update


Skye Bioscience Press release: Study Update

Oct 6, 2025, 8:00 AM EDT - 9 months ago

Skye Bioscience Press release: Study Update


Skye Bioscience Slides: Study Update

Oct 6, 2025, 8:00 AM EDT - 9 months ago

Skye Bioscience Slides: Study Update


Skye Bioscience Slides: Corporate Presentation

Sep 10, 2025, 7:00 AM EDT - 10 months ago

Skye Bioscience Slides: Corporate Presentation


Skye Bioscience Transcript: KOL Event

Sep 4, 2025, 8:00 AM EDT - 10 months ago

Skye Bioscience Transcript: KOL Event


Skye Bioscience Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Skye Bioscience Earnings Call Transcript: Q2 2025


Skye Bioscience Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Skye Bioscience Quarterly report: Q2 2025


Skye Bioscience Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Skye Bioscience Earnings release: Q2 2025


Skye Bioscience Slides: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Skye Bioscience Slides: Q2 2025


Fellforit
Fellforit Jun. 24 at 9:13 PM
$SKYE hey mission trader--while you're swinging for the fences "hoping" for a foul tip, ive been hitting home runs!!! Has your man Dhillion given you a participation trophy yet??
0 · Reply
MissionaryTrader
MissionaryTrader Jun. 24 at 5:03 PM
$SKYE added again
1 · Reply
MissionaryTrader
MissionaryTrader Jun. 23 at 4:16 PM
$SKYE added
1 · Reply
YazzJr
YazzJr Jun. 23 at 12:55 PM
$SKYE Interesting video. Muscle loss is a real issue when taking a GLP-1's. There are things people can do to counter-act that like working out and eating a lot of protein but, let's face it, the people who need the GLP-1's are people who never worked out or minded their protein intake so changing that lifestyle will be hard. This is why Nimicimab is so important. It works for losing the fat but, it doesn't effect muscle tissue at all. Anyway, interesting video for those who care to watch. https://www.youtube.com/watch?v=Zit5we5Ss18
0 · Reply
Lucoz12
Lucoz12 Jun. 23 at 12:16 PM
$SKYE new 8-K out today, worth reading carefully because it's not the PIPE everyone was waiting for and it's not a delisting either. Nasdaq approved SKYE's transfer from the Nasdaq Global Market to the Nasdaq Capital Market effective June 23. The Capital Market only requires $3M stockholders' equity instead of the $10M that triggered the deficiency, and with equity around $9M they're now comfortably compliant. Same ticker, same exchange, no forced ETF selling. Basically they solved the equity problem without diluting, they lowered the bar instead of issuing emergency shares at a low price. Two things still open, the sub-$1 bid price with the September deadline so a reverse split is still possible, and the cash side. But the June 29 pressure is off the table now, they bought themselves time to raise capital from a less desperate position or to close a deal without having to dilute first 🤞🏻
1 · Reply
Blinddartthrowerl
Blinddartthrowerl Jun. 18 at 4:00 AM
$SKYE The RS will probably be 1:25 this time - thats a lot better than the last one 1:250!!! I’m a triathelete too!!!!
0 · Reply
Blinddartthrowerl
Blinddartthrowerl Jun. 18 at 3:56 AM
$SKYE Did these guys cure Glaucoma yet?
0 · Reply
Blinddartthrowerl
Blinddartthrowerl Jun. 18 at 3:55 AM
$SKYE Did these guys cure Glaucoma yet?
0 · Reply
TheMoneyDude777
TheMoneyDude777 Jun. 16 at 9:07 PM
$SKYE thank you awesome job! now though bad management lets get this to .5 To the floor!!!
1 · Reply
TheMoneyDude777
TheMoneyDude777 Jun. 16 at 1:47 PM
$SKYE close today under .68! yes summer dilution!
0 · Reply
TheMoneyDude777
TheMoneyDude777 Jun. 16 at 11:10 AM
$SKYE .69 incoming lol
0 · Reply
Fellforit
Fellforit Jun. 15 at 8:07 PM
$SKYE oh its buying time again...
0 · Reply
TheMoneyDude777
TheMoneyDude777 Jun. 15 at 7:54 PM
$SKYE lol who would have guessed this would go back to .7 shocker lol
0 · Reply
YazzJr
YazzJr Jun. 11 at 7:09 PM
$SKYE It looked interesting there for a minute.
1 · Reply
MissionaryTrader
MissionaryTrader Jun. 10 at 12:28 PM
2 · Reply
Polsky
Polsky Jun. 10 at 11:10 AM
$SKYE it is really active here? lol
0 · Reply
TheMoneyDude777
TheMoneyDude777 Jun. 8 at 11:53 AM
$SKYE very nice now lets see this close under .7
0 · Reply
MissionaryTrader
MissionaryTrader Jun. 3 at 12:40 PM
$SKYE https://www.cnbc.com/2026/06/03/eli-lilly-to-use-glp-1-windfall-to-fund-ma-and-diversify-pipeline.html
1 · Reply
TheMoneyDude777
TheMoneyDude777 Jun. 3 at 12:21 PM
$SKYE easy close under .68
0 · Reply
TheMoneyDude777
TheMoneyDude777 Jun. 3 at 8:21 AM
$SKYE Woot .7 today! that was fast RS coming for sure! cheer for dirty management!
0 · Reply
Fellforit
Fellforit Jun. 2 at 7:32 PM
$SKYE follow the missionary man-buy, buy, buy...
0 · Reply
TheMoneyDude777
TheMoneyDude777 Jun. 2 at 7:26 PM
$SKYE keep up the great work! please
0 · Reply